Did you know?
Saccharomyces boulardii is a probiotic yeast, not a bacterium, so antibiotics do not kill it. That is exactly why it can be taken alongside a course of antibiotics to help prevent the diarrhea they often cause.
Saccharomyces boulardii is a probiotic yeast, a thermotolerant strain of Saccharomyces cerevisiae, used for decades against diarrheal illness. Because it is a eukaryote, antibacterial antibiotics do not kill it, which makes it uniquely suited to preventing antibiotic-associated diarrhea. Its strongest evidence is for antibiotic-associated and traveler's diarrhea, with emerging support for Clostridioides difficile recurrence.
Microbiome-targeted interventions (MBTIs) are validated using a dual-evidence logical framework. First, the intervention must realign the condition’s microbiome signature by increasing beneficial taxa that are consistently depleted and reducing pathogenic taxa that are consistently enriched. Second, the intervention must demonstrate measurable clinical benefit. Concordance of these effects in the same context validates the intervention as an MBTI and supports the clinical relevance of the microbiome signature.
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreSaccharomyces boulardii is a probiotic yeast that has been used for decades to prevent and treat diarrheal illness. Genetically it is a thermotolerant strain of Saccharomyces cerevisiae (S. cerevisiae var. boulardii); the widely studied commercial strain is designated CNCM I-745. It was isolated in the 1920s by Henri Boulard from tropical fruit in Indochina, where the peel was reportedly used against diarrheal symptoms.[1]
What makes S. boulardii distinctive is that it is a eukaryote, a yeast rather than a bacterium, so antibacterial antibiotics do not kill it. That single property is why it can be taken alongside a course of antibiotics to prevent the diarrhea they often cause, its best-supported use.[1][2] Unlike the data-derived taxon pages on this site, which are built from differential-abundance signatures, this page is assembled from the clinical-trial and guideline literature, because S. boulardii is studied primarily as a therapeutic rather than as a differential microbiome taxon.
S. boulardii is a single-celled fungus (yeast) that reproduces by budding. It grows best at human body temperature, about 37°C, an unusual trait among S. cerevisiae strains and one reason it is well adapted to the gut.[1] It does not permanently colonize the intestine: it reaches steady levels within a few days of dosing and clears within days of stopping, so continuous administration is needed for a sustained effect.[2]
S. boulardii's benefits come from a few complementary mechanisms rather than from colonizing the gut.
| Mechanism | Description |
|---|---|
| Antibiotic resistance (eukaryote) | As a yeast it is intrinsically unaffected by antibacterial antibiotics, so it survives in the gut during antibiotic therapy and can act exactly when antibiotic-associated dysbiosis occurs.[1] |
| Microbiota support and resilience | It helps the disrupted gut microbiota recover and return toward its pre-antibiotic state, supporting the community's natural resilience.[1] |
| Gut-barrier and anti-diarrheal effects | It supports the intestinal barrier and counters pathogen- and antibiotic-associated diarrhea, the basis of its efficacy across several diarrheal conditions.[2] |
| Transient, dose-dependent action | Because it does not colonize, benefit tracks with adequate, timely dosing, ideally started with the antibiotic or within 48 hours.[1] |
The table below summarizes the clinical evidence for S. boulardii by condition, drawn from randomized trials, meta-analyses, and professional-society guidelines. The strength column reflects that clinical-trial and guideline evidence, which is a different basis from the methodology grade (A·D·S·C·R) used on this site's data-derived signature pages; it is not medical advice.
| Condition | What the evidence shows | Strength |
|---|---|---|
| Antibiotic-associated diarrhea (prevention) | Significantly reduces the risk of antibiotic-associated diarrhea; an adult meta-analysis found a relative risk of 0.47, and pediatric guidelines give a strong recommendation at moderate certainty.[2][3][4] | Strong |
| Traveler's diarrhea (prevention) | Reduces the risk of traveler's diarrhea; strongly recommended for adults in the pooled analysis.[2] | Moderate |
| Clostridioides difficile diarrhea (prevention of recurrence) | Shows promise for preventing recurrence; a professional guideline offers a conditional suggestion at low certainty, so it is supportive rather than definitive.[2][3] | Emerging |
| Enteral-nutrition-related diarrhea | Randomized trials support a reduction in diarrhea in tube-fed patients.[2] | Moderate |
| Helicobacter pylori eradication (adjunct) | Added to H. pylori eradication therapy, it reduces treatment-related side effects and symptoms.[2] | Moderate |
| Acute diarrhea (children and adults) | May shorten the duration of acute diarrhea; evidence is supportive but not yet definitive.[2][4] | Emerging |
| IBS, Crohn's disease, giardiasis, HIV-related diarrhea | Early trials suggest possible benefit, but the evidence is insufficient to recommend for these indications.[2] | Investigational |
S. boulardii is generally well tolerated. In the adult meta-analysis it was both safe and effective in 84% of treatment arms, and the pediatric Cochrane review found low adverse-event rates with no serious events attributable to probiotics in the trials.[2][4]
The important exception is that, because it is a live yeast, rare cases of fungemia (a bloodstream yeast infection) have occurred, essentially confined to severely ill or immunocompromised patients, especially those with a central venous catheter. For that reason it should be avoided or used only with medical guidance in critically ill, immunocompromised, or central-line patients.[4]
Clinical use is guided by clinicians; the entries below are classified by our validation method and are not medical advice.
| Use | Class | Status |
|---|---|---|
| Prevention of antibiotic-associated diarrhea | Probiotic | Validated |
| Prevention of traveler's diarrhea | Probiotic | Validated |
| Adjunct to H. pylori eradication | Probiotic | Validation In Progress |
| Prevention of C. difficile recurrence | Probiotic | Validation In Progress |
For antibiotic-associated diarrhea, the benefit depends on adequate dosing started early, ideally with the antibiotic or within 48 hours, and continued through the antibiotic course; because the yeast does not colonize, the effect fades after stopping.[1] Specific strains and doses are studied products, so effects are strain-specific and are not guaranteed to generalize across all preparations.[1]
2026-07-04
Saccharomyces boulardii majorPage created from the clinical-trial and guideline literature (no differential-abundance corpus data): biology, mechanism, a curated Evidence-by-condition table with guideline-graded strength, safety, and interventions.
Waitzberg D, Guarner F, Hojsak I, Ianiro G, Polk DB, Sokol H.
Can the evidence-based use of probiotics (notably Saccharomyces boulardii CNCM I-745 and Lactobacillus rhamnosus GG) mitigate the clinical effects of antibiotic-associated dysbiosis?Adv Ther. 2024
McFarland LV.
Systematic review and meta-analysis of Saccharomyces boulardii in adult patients.World J Gastroenterol. 2010
Szajewska H, Canani RB, Guarino A, Hojsak I, Indrio F, Kolacek S, Orel R, Shamir R, Vandenplas Y, van Goudoever JB, Weizman Z.
Probiotics for the prevention of antibiotic-associated diarrhea in children.J Pediatr Gastroenterol Nutr. 2016
Guo Q, Goldenberg JZ, Humphrey C, El Dib R, Johnston BC.
Probiotics for the prevention of pediatric antibiotic-associated diarrhea.Cochrane Database Syst Rev. 2019
Overview
Interventions
FAQs
Update History
References